Moderator of 2 Sessions
Session Description: This practical interactive session chaired by Prof. Ohad Cohen and Madison Smith, will walk you through the new Medtronic Smart MDI system and how smart pen systems are transforming MDI therapy, showing that CGM alone is not enough anymore. The key features of the Smart MDI system will be presented and followed by some first experience cases and healthcare provider insights. The participants will be able to comment and share their experiences and insights.
Session Description: This practical interactive session chaired by Prof. Ohad Cohen will focus on simplifying complex meal management by the MiniMed™ 780G system, as will be exemplified by meals from all over the globe, aiming to achieve the highest possible glycemic control while minimizing the demands on users and caretakers. Maya Laron Hirsh, head dietitian at Sheba Medical Center Diabetes institute, will demonstrate meal handling of a complex Mediterranean cuisine, Francesca Gulotta, a Medtronic clinical specialist from Italy, will demonstrate managing high carbohydrate diet and Heather Lackey from the USA, Director of global medical education at Medtronic will provide insights on “supersized“ fast foods. The participants will be able to comment and share their experiences and insights.
Presenter of 7 Presentations
Introduction (ID 1152)
Insulin-to-carb ratios and the burden of carb counting using the MiniMed™ 780G system (ID 1157)
Questions & Answers (ID 1151)
Q&A (ID 1154)
Q&A (ID 1160)
CGM alone is not enough (ID 1148)
OP019 - 12-MONTH RESULTS OF THE ADAPT RANDOMIZED CONTROLLED TRIAL: ADVANCED HYBRID CLOSED LOOP THERAPY VERSUS CONVENTIONAL TREATMENT IN ADULTS WITH TYPE 1 DIABETES (ID 329)
Abstract
Background and Aims
The ADAPT trial1 demonstrated a significant 1.4% reduction in HbA1c with Advanced Hybrid Closed Loop (AHCL) therapy, when adults with type 1 diabetes using multiple daily injections plus intermittently scanned continuous glucose monitoring (MDI+isCGM, HbA1c>8.0%) were randomized to AHCL (MiniMed™ 780G) or continued current treatment. Time in range (TIR) improved (27.6%) as well while safety remained. We investigated (1) whether these achievements were reproduced in the MDI+isCGM arm after individuals switched to AHCL, and (2) whether the successful outcomes in the AHCL arm were maintained after 12 months.
Methods
Endpoints are within-arm changes in HbA1c and other parameters of glycemic control from 6 to 12 months.
Results
Thirty-five patients in the AHCL arm and 32 in the MDI+isCGM arm completed follow-up. The figure and table show glycemic control over time. The MDI+isCGM arm, switching to AHCL therapy, repeated the successful improvement in HbA1c (change: -1.36%. 95%CI: -1.65% to -1.08%) and other parameters. In the AHCL arm, HbA1c (7.4%) and other parameters were maintained. After 12 months, there was no more between-arm difference in HbA1c decrease (0.1; -0.30 to 0.52).
Conclusions
This analysis showed that the substantial efficacy improvement as seen in the ADAPT1 publication was reproduced in the control arm and sustained after 12 months. These data further support expanded access of MiniMed™ 780G system to those with poorly controlled type 1 diabetes at an early stage.
1 Choudhary et al., Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT), Lancet Diabetes Endocrinol. 2022 Oct;10(10)